申请人:Takeda Pharmaceutical Company Limited
公开号:EP1845081A1
公开(公告)日:2007-10-17
The present invention relate to a compound represented by the formula (I) or (II)
wherein
ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine),
ring B is an optionally substituted aromatic ring,
ring D is an optionally substituted ring,
R1 and R2 are each independently a hydrogen atom or a substituent,
R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring,
ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N,
Ra1 is an optionally substituted hydrocarbon group, and
Ra2 and Ra3 are each independently a hydrogen atom or a substituent,
or a salt thereof.
The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.
本发明涉及由式 (I) 或 (II) 所代表的化合物
其中
环 A 是任选取代的环(该环不应是吡咯烷、哌啶和哌嗪)、
环 B 是任选取代的芳香环
环 D 是任选取代的环、
R1 和 R2 各自独立地为氢原子或取代基、
R3 是氢原子或 C1-6 烷基,或 R3 与环 A 键合形成非芳香环、
环 Aa 是任选取代的芳香烃,Y 是 CH 或 N、
Ra1 是任选取代的烃基,以及
Ra2 和 Ra3 各自独立地为氢原子或取代基、
或其盐。
本发明提供了一种具有 DGAT 抑制活性的化合物,可用于治疗或改善由 DGAT 高表达或高活化引起的疾病或病理现象。